The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?

被引:146
作者
Bronner, Christian
Achour, Mayada
Arima, Yoshimi
Chataigneau, Thierry
Saya, Hideyuki
Schini-Kerth, Valerie B.
机构
[1] Fac Pharm, Dept Pharmacol & Pharmacochim Interact Mol & Cell, CNRS, UMR 7175, F-67401 Illkirch Graffenstaden, France
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan
关键词
cancer; E3; ligases; ICBP90; Np95; oncogenes; UHRF;
D O I
10.1016/j.pharmthera.2007.06.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
in this paper, we review the current literature about the UHRF family that in particular includes the UHRF1 and UHRF2 genes. Its members play a fundamental role in cell proliferation through different structural domains. These domains include a ubiquitin-like domain (NIRF_N), a plant homeodomain (PHD) domain, a SRA domain and a RING domain. The SRA domain has only been observed in this family probably conferring unique properties to it. The unique enzymatic activity so far identified in this family involves the RING finger that contains a ubiquitin E3 ligase activity toward, for instance, histones. The physiological roles played by the UHRF family are most likely exerted during embryogenic development and when proliferation is required in adults. Interestingly, UHRF members are putative oncogenes regulated by tumor suppressor genes, but they exert also a feedback control on these latter. Finally, we propose some new roles for this family, including regulation and/or inheritance of the epigenetic code. Alteration of these regulatory mechanisms, such as those occurring in cancer cells, may be involved in carcinogenesis. The reasons why the UHRF family could be an interesting target for developing anticancer drugs is also developed. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:419 / 434
页数:16
相关论文
共 123 条
[1]   Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions [J].
Anderson, Kenneth C. .
EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) :155-162
[2]   Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition [J].
Arima, Y ;
Hirota, T ;
Bronner, C ;
Mousli, M ;
Fujiwara, T ;
Niwa, S ;
Ishikawa, H ;
Saya, H .
GENES TO CELLS, 2004, 9 (02) :131-142
[3]   DNA methylation and the regulation of gene transcription [J].
Attwood, JT ;
Yung, RL ;
Richardson, BC .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (02) :241-257
[4]   Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J].
Bachman, KE ;
Park, BH ;
Rhee, I ;
Rajagopalan, H ;
Herman, JG ;
Baylin, SB ;
Kinzler, KW ;
Vogelstein, B .
CANCER CELL, 2003, 3 (01) :89-95
[5]   Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain [J].
Bannister, AJ ;
Zegerman, P ;
Partridge, JF ;
Miska, EA ;
Thomas, JO ;
Allshire, RC ;
Kouzarides, T .
NATURE, 2001, 410 (6824) :120-124
[6]   The Arabidopsis thaliana genome contains at least 29 active genes encoding SET domain proteins that can be assigned to four evolutionarily conserved classes [J].
Baumbusch, LO ;
Thorstensen, T ;
Krauss, V ;
Fischer, A ;
Naumann, K ;
Assalkhou, R ;
Schulz, I ;
Reuter, G ;
Aalen, RB .
NUCLEIC ACIDS RESEARCH, 2001, 29 (21) :4319-4333
[7]   Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry [J].
Bonapace, IM ;
Latella, L ;
Papait, R ;
Nicassio, F ;
Sacco, A ;
Muto, M ;
Crescenzi, M ;
Di Fiore, PP .
JOURNAL OF CELL BIOLOGY, 2002, 157 (06) :909-914
[8]   Tip60 is a nuclear hormone receptor coactivator [J].
Brady, ME ;
Ozanne, DM ;
Gaughan, L ;
Waite, I ;
Cook, S ;
Neal, DE ;
Robson, CN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) :17599-17604
[9]   The antiapoptotic protein ICBP90 is a target for protein kinase 2 [J].
Bronner, C ;
Trotzier, MA ;
Filhol, O ;
Cochet, C ;
Rochette-Egly, C ;
Schöller-Guinard, M ;
Klein, JP ;
Mousli, M .
SIGNAL TRANSDUCTION PATHWAYS, CHROMATIN STRUCTURE, AND GENE EXPRESSION MECHANISMS AS THERAPEUTIC TARGETS, 2004, 1030 :355-360
[10]  
Bronner C, 2002, ANTICANCER RES, V22, P605